Rhythm Pharmaceuticals (RYTM) News
NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
112.36-4.44 (-3.80%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RYTM news summary
We found 14 recent headlines mentioning Rhythm Pharmaceuticals (RYTM): 1 in the past week and 11 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. For price context, RYTM is down 3.80% at $112.36. The most recent story, "Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026", was published by GlobeNewswire on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Rhythm Pharmaceuticals headlines
- Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –GlobeNewswire
- Rhythm Pharmaceuticals gains on report of additional bidderSeeking Alpha
- Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid reportInvesting.comRYTM, AZN
- Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm…GlobeNewswire
- Rhythm Pharmaceuticals, Inc. Reports Third Quarter 2026 Net Product Revenue of $92.1 millionRhythm Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, with net product revenue from global sales of IMCIVREE reaching $92.1 million, representing…Nasdaq
- Rhythm Pharmaceuticals GAAP EPS of -$0.61 beats by $0.10, revenue of $92.1M beats by $7.5MSeeking Alpha
- Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue EstimatesRhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +10.29% and +9.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the…NasdaqRYTM, TECH
- Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026…GlobeNewswire
- Rhythm Amends LG Chem Deal, Secures Up To $750 Million Financing For Obesity Pipeline(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) has amended its licensing agreement with LG Chem for bivamelagon, an investigational oral therapy for rare obesity disorders, while also securing…NasdaqKKR, RYTM, HEI.A
- Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem…GlobeNewswire
- Rhythm Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha
- Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with…GlobeNewswire
- Rhythm Launches Imcivree In Japan For Acquired Hypothalamic Obesity(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced the commercial launch of Imcivree (setmelanotide) in Japan for acquired hypothalamic obesity, following its inclusion on the country's…NasdaqRYTM, BRK.B
- Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan…GlobeNewswire